Cigna Group (NYSE:CI) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPS

01 Aug 2026, 11:56 by Jessica Moore · The Cerbat Gem

Cigna Group (NYSE:CI – Get Free Report) issued its quarterly earnings results on Thursday. The health services provider reported $7.78 EPS for the quarter, topping the consensus estimate of $7.60 by $0.18, Zacks reports. The business had revenue of $70.04 billion for the quarter, compared to analysts’ expectations of $70.14 billion. Cigna Group had a net margin of 2.27% and a return on equity of 19.75%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the company posted $7.20 earnings per share. Cigna Group updated its FY 2026 guidance to 30.450- EPS.

Here are the key takeaways from Cigna Group’s conference call:

Second-quarter results exceeded expectations: revenue reached $71.7 billion and adjusted EPS was $7.78, prompting Cigna to raise its 2026 adjusted EPS outlook to at least $30.45.
Evernorth Specialty and Care Services adjusted earnings grew 22% year over year to $1.1 billion, supported by specialty utilization, faster biosimilar and specialty-generic adoption, operating efficiencies, and contributions from Shields Health Solutions.
Cigna Healthcare adjusted earnings rose 17%, with membership growth in the U.S. employer business and slightly favorable medical-cost experience; full-year segment earnings guidance increased to at least $4.55 billion.
Evernorth Pharmacy Benefit Services earnings declined to $609 million due to large contract renewals and investments in the rebate-free Signature model, while moderating GLP-1 utilization and faster biosimilar adoption are expected to pressure the business through the rest of 2026.
Management continues investing in AI-enabled programs such as Pharmacy Forward and enhanced care coordination, which it says could cut specialty therapy-start times in half, support 20% more customers with complex needs, and reduce avoidable inpatient stays.

Cigna Group Stock Down 2.9%

CI traded down $8.39 during midday trading on Friday, hitting $279.27. 2,187,775 shares of the company’s stock traded hands, compared to its average volume of 1,509,540. The company has a market cap of $73.88 billion, a PE ratio of 11.55, a price-to-earnings-growth ratio of 1.11 and a beta of 0.29. The stock’s fifty day simple moving average is $286.62 and its 200-day simple moving average is $281.10. Cigna Group has a one year low of $239.51 and a one year high of $315.47. The company has a debt-to-equity ratio of 0.68, a current ratio of 0.76 and a quick ratio of 0.73.

Cigna Group Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Tuesday, September 8th will be issued a dividend of $1.56 per share. This represents a $6.24 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Tuesday, September 8th. Cigna Group’s dividend payout ratio (DPR) is currently 26.45%.

Insiders Place Their Bets

In related news, CAO Jamie G. Kates sold 899 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $298.61, for a total transaction of $268,450.39. Following the completion of the transaction, the chief accounting officer owned 2,368 shares of the company’s stock, valued at approximately $707,108.48. The trade was a 27.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David Cordani sold 201,878 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $292.82, for a total transaction of $59,113,915.96. Following the completion of the sale, the chief executive officer directly owned 34,337 shares of the company’s stock, valued at approximately $10,054,560.34. This trade represents a 85.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.60% of the stock is owned by insiders.

Institutional Trading of Cigna Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Compound Planning Inc. boosted its position in shares of Cigna Group by 2.7% during the fourth quarter. Compound Planning Inc. now owns 1,944 shares of the health services provider’s stock worth $535,000 after purchasing an additional 51 shares in the last quarter. Invesco Ltd. raised its holdings in Cigna Group by 27.4% during the fourth quarter. Invesco Ltd. now owns 2,421,775 shares of the health services provider’s stock worth $666,545,000 after acquiring an additional 521,273 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its position in shares of Cigna Group by 8.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 47,873 shares of the health services provider’s stock valued at $13,176,000 after acquiring an additional 3,654 shares during the period. Virtue Capital Management LLC bought a new position in shares of Cigna Group during the 4th quarter worth approximately $272,000. Finally, Vident Advisory LLC grew its stake in Cigna Group by 80.5% in the 4th quarter. Vident Advisory LLC now owns 16,210 shares of the health services provider’s stock valued at $4,462,000 after buying an additional 7,230 shares during the last quarter. 86.99% of the stock is owned by institutional investors.

Key Stories Impacting Cigna Group

Here are the key news stories impacting Cigna Group this week:

Positive Sentiment: Cigna reported adjusted second-quarter earnings of $7.78 per share, above the roughly $7.60 consensus estimate, while revenue rose 7% year over year to approximately $71.7 billion. Cigna Healthcare revenue increased 9%, and Evernorth Health Services revenue grew 6%. Cigna Q2 results and outlook
Positive Sentiment: Management raised its 2026 adjusted earnings outlook to at least $30.45 per share, implying approximately 10% earnings growth, supported by strength across the healthcare and pharmacy-benefit businesses. Cigna raises annual profit forecast
Positive Sentiment: Analyst sentiment remains constructive: Barclays raised its price target from $304 to $310 while retaining an “equal weight” rating. A separate analysis highlighted CI’s discounted valuation, ongoing share repurchases, strong cash generation, and $1.56-per-share dividend. Cigna valuation analysis
Neutral Sentiment: The earnings beat was accompanied by revenue that was slightly below some analyst estimates, and Barclays’ “equal weight” stance suggests the improved outlook may already be partly reflected in the stock.
Negative Sentiment: Cigna expects lower growth in prescriptions for popular GLP-1 drugs. Because these treatments are a significant growth area for pharmacy services, slower utilization could temper future revenue and profit expansion. Cigna GLP-1 prescription outlook
Negative Sentiment: Elevated medical costs and higher pharmacy expenses remain industrywide risks. Those pressures may explain why investors initially treated the guidance increase cautiously despite Cigna’s higher profit and broad-based operating growth.

Wall Street Analyst Weigh In

Several brokerages have recently commented on CI. Deutsche Bank Aktiengesellschaft lowered Cigna Group from a “buy” rating to a “hold” rating and decreased their target price for the stock from $303.00 to $302.00 in a research report on Wednesday, May 20th. Raymond James Financial set a $340.00 price objective on shares of Cigna Group in a report on Friday, May 1st. Royal Bank Of Canada lifted their price target on shares of Cigna Group from $333.00 to $337.00 and gave the company an “outperform” rating in a report on Friday, May 1st. Sanford C. Bernstein increased their price objective on shares of Cigna Group from $371.00 to $381.00 and gave the stock an “outperform” rating in a research note on Thursday, July 9th. Finally, Robert W. Baird set a $362.00 price objective on Cigna Group in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $341.60.

Get Our Latest Report on CI

About Cigna Group

(Get Free Report)

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.